Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan


(July 18, 2018) - - Statement: Our ability to build a market for safe, effective biosimilar products is key for patients and our nation’s health care system. It’s a key to promoting access and reducing health care costs. And it’s ...